| All Releases |
|---|
 |
Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation
Dec 20, 2011
|
18.2 KB
|
| |
NDA Submission Targeted for Mid 2012
RALEIGH, N.C. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals,
Inc. (NASDAQ:PGNX) today announced the successful outcome of the Phase 3
trial to evaluate the efficacy and safety of oral methylna...
|
|
|
Progenics Pharmaceuticals Announces Third Quarter 2011 Financial Results
Nov 9, 2011
|
33.2 KB
|
| |
TARRYTOWN, N.Y., Nov. 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced third quarter 2011 results of operations.
"We have been pleased by the efforts of our partner Salix during this second quarter commercializing RELISTOR," said Mark R. Baker, Progenics' chief executive officer. "We look forward to ...
|
|
|
Progenics Pharmaceuticals to Participate in Investor Conferences
Nov 8, 2011
|
19.0 KB
|
| |
TARRYTOWN, N.Y., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at two upcoming investor conferences in New York City:
Brean Murray, Carret & Co. 2011 Life Sciences Summit beginning at 8:00 a.m. Eastern Time on Monday, November 14
8th Annual Lazard ...
|
|
|
Progenics to Host Conference Call to Review Third Quarter 2011 Financial Results on November 9
Nov 3, 2011
|
18.5 KB
|
| |
TARRYTOWN, N.Y., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) will host a conference call and webcast to discuss its financial results for the third quarter of 2011 on Wednesday, November 9, 2011 at 8:30 a.m. Eastern Time.
To join the conference call, please dial 877-250-8889 (domestic) or 720-545-0001 (int...
|
|
|
Progenics Pharmaceuticals to Present at NewsMakers Conference
Oct 14, 2011
|
17.8 KB
|
| |
TARRYTOWN, N.Y., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at the 18th Annual "NewsMakers in the Biotech Industry" conference sponsored by BioCentury and Thomson Reuters on Friday, October 21st in New York City. The 3:00 p.m. Eastern time presentation will be webcast live on...
|
|
|
Progenics Pharmaceuticals to Present at UBS Global Life Sciences Conference
Sep 16, 2011
|
18.3 KB
|
| |
TARRYTOWN, N.Y., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that Chief Executive Officer Mark R. Baker will present at the UBS Global Life Sciences Conference on Monday, September 19 at 9:00 a.m. EDT. The presentation will be webcast live and will be archived for 30 days on the Events page of Pr...
|
|
|
Progenics Pharmaceuticals Announces Strategic Focus on Oncology
Sep 15, 2011
|
25.5 KB
|
| |
— Highlights actions resulting from strategic review —
— Conference call and webcast today at 8:30 a.m. ET —
TARRYTOWN, N.Y., Sept. 15, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced strategic, operational, organizational and financial changes resulting from a review ...
|
|
|
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR® in Patients with Non-Cancer Pain
Aug 30, 2011
|
18.1 KB
|
| |
— PDUFA Action Date is April 27, 2012 —
TARRYTOWN, N.Y. & RALEIGH, N.C.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals,
Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug
Administration (FDA) has accepted for filing a supple...
|
|
|
Progenics Pharmaceuticals Announces Second Quarter 2011 Financial Results
Aug 9, 2011
|
32.5 KB
|
| |
— Second quarter U.S. sales of RELISTOR® increased 99% over first quarter and 50% over prior year quarter —
— Enrollment in phase 3 trial of oral methylnaltrexone completed —
— Conference call and webcast at 8:30 am ET today —
TARRYTOWN, N.Y., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Progeni...
|
|
|
Progenics to Host Conference Call to Review Second Quarter 2011 Financial Results on August 9
Aug 2, 2011
|
7.7 KB
|
| |
TARRYTOWN, N.Y., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the second quarter of 2011 on Tuesday, August 9, 2011 at 8:30 a.m. ET.
To join the conference call, please dial 877-250-8889 (domestic) or 720...
|
|
|
Progenics Submits RELISTOR(R) Supplemental NDA for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-Cancer Pain
Jun 28, 2011
|
20.9 KB
|
| |
TARRYTOWN, N.Y., June 28, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval for the use of RELISTOR® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-i...
|
|
|
Progenics Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference
Jun 2, 2011
|
19.8 KB
|
| |
TARRYTOWN, N.Y., June 2, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that Mark Baker, the Company's chief executive officer, will present a company update at the Jefferies 2011 Global Healthcare Conference in New York on Monday, June 6, 2011 at 10:30 a.m. ET.
The presentation will be available via ...
|
|
|
Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients
May 20, 2011
|
69.9 KB
|
| |
TARRYTOWN, N.Y., May 20, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today provided analyses of safety and efficacy endpoints from the 1,034-patient, one-year phase 3 safety study of methylnaltrexone bromide subcutaneous injection in non-malignant pain patients with opioid-induced constipation (OIC). At a fixed dose of 12...
|
|
|
Progenics Pharmaceuticals Announces First Quarter 2011 Financial Results
May 10, 2011
|
20.1 KB
|
| |
TARRYTOWN, N.Y., May 10, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31.
"The most significant event of our first quarter was completing a license agreement for RELISTOR® with Salix Pharmaceuticals," said Mark R. Baker, Progenics' chief exe...
|
|
|
Progenics to Host First Quarter 2011 Financial Results Conference Call and Webcast May 10
May 9, 2011
|
8.5 KB
|
| |
TARRYTOWN, N.Y., May 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the first quarter of 2011 on Tuesday May 10, 2011 at 8:30 a.m. ET.
To participate in the conference call, please dial 888-262-8720 (domestic) or 9...
|
|
|
Progenics Pharmaceuticals to Webcast Upcoming Presentations
Apr 4, 2011
|
10.4 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that Mark
Baker, the Company's chief executive officer, will deliver company
updates at the 10th Annual Needham Healthcare Conference on Tuesday,
April 5, 2011 at 4:00pm ET, and at BioCentury's Future Leaders in the
...
|
|
|
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2010 Financial Results
Mar 15, 2011
|
21.2 KB
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the fourth quarter and year ended December 31,
2010.
Financial Results
Net loss for the fourth quarter was $18.8 million or $0.57, basic and
...
|
|
|
Progenics Pharmaceuticals Announces Changes in Executive Responsibilities
Mar 9, 2011
|
12.3 KB
|
| |
– Mark R. Baker named chief executive officer –
– Founder Paul J. Maddon, M.D., Ph.D. appointed vice chairman –
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it
has appointed Mark R. Baker chief executive officer. Prior...
|
|
|
Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC
Feb 17, 2011
|
13.5 KB
|
| |
- Data Presented at Genitourinary Cancers Symposium -
TARRYTOWN, N.Y. & ORLANDO, Fla.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today reported positive
preliminary data from an ongoing phase 1 study of PSMA ADC, an
antibody-drug conjugate (ADC) designed to selectively...
|
|
|
Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®
Feb 7, 2011
|
21.7 KB
|
| |
– RELISTOR Currently Marketed as First-in-Class Treatment for
Opioid-Induced Constipation in Advanced Illness Patients –
– Supplemental NDA Submission Planned in 2011 to Potentially
Expand Market to Chronic, Non-Malignant Pain –
– Phase 3 Trial of Oral RELISTOR in Chronic, Non-Mali...
|
|
|
